NASDAQ:KZIA Novogen (KZIA) Stock Price, News & Analysis $7.00 +0.01 (+0.14%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$6.88 -0.12 (-1.77%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novogen Stock (NASDAQ:KZIA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novogen alerts:Sign Up Key Stats Today's Range$6.79▼$7.0650-Day Range$6.31▼$8.5052-Week Range$2.86▼$39.05Volume28,225 shsAverage Volume187,677 shsMarket Capitalization$11.55 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingModerate Buy Company Overview Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology. Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide. The company benefits from strategic partnerships and licensing arrangements designed to advance its lead programs through clinical trials while expanding its preclinical pipeline into additional tumor types. Novogen’s global footprint enables access to diverse patient populations and fosters collaborations in neuroscience and oncology research. Under the leadership of Chief Executive Officer Dr. Daniel Goldstein, Novogen continues to prioritize the rapid development of its clinical candidates through regulatory milestones. The management team combines expertise in medicinal chemistry, clinical development, and regulatory affairs to streamline translational research and engage with key opinion leaders. Through ongoing clinical trials and data readouts, Novogen aims to demonstrate the safety and efficacy of its novel small molecule therapies and to establish strategic partnerships for commercialization.AI Generated. May Contain Errors. Read More Novogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreKZIA MarketRank™: Novogen scored higher than 75% of companies evaluated by MarketBeat, and ranked 223rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingNovogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialNovogen has a consensus price target of $16.50, representing about 135.7% upside from its current price of $7.00.Amount of Analyst CoverageNovogen has only been the subject of 2 research reports in the past 90 days.Read more about Novogen's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about Novogen's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.96% of the outstanding shares of Novogen have been sold short.Short Interest Ratio / Days to CoverNovogen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novogen has recently decreased by 67.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovogen does not currently pay a dividend.Dividend GrowthNovogen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.96% of the outstanding shares of Novogen have been sold short.Short Interest Ratio / Days to CoverNovogen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novogen has recently decreased by 67.42%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentNovogen has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Novogen this week, compared to 0 articles on an average week.Search Interest3 people have searched for KZIA on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Novogen is held by insiders.Percentage Held by InstitutionsOnly 30.89% of the stock of Novogen is held by institutions.Read more about Novogen's insider trading history. Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KZIA Stock News HeadlinesKazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader ProgramOctober 7, 2025 | prnewswire.comKazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy RegimenOctober 2, 2025 | prnewswire.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone. | Porter & Company (Ad)Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMGOctober 1, 2025 | prnewswire.comKazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib MonotherapySeptember 11, 2025 | prnewswire.comKazia Therapeutics Announces $2 Million Private Placement at Premium to MarketAugust 1, 2025 | prnewswire.comKazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialJuly 9, 2025 | prnewswire.comKazia Therapeutics Shares Jump After Data Shows Lead Asset Could Treat Breast CancerJune 11, 2025 | marketwatch.comSee More Headlines KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed this year? Novogen's stock was trading at $8.85 at the beginning of the year. Since then, KZIA shares have decreased by 20.9% and is now trading at $7.00. When did Novogen's stock split? Novogen shares reverse split before market open on Monday, October 28th 2024.The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Novogen? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novogen investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Today10/19/2025Next Earnings (Estimated)11/21/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KZIA Previous SymbolASX:KZA CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees12Year Founded1994Price Target and Rating Average Price Target for Novogen$16.50 High Price Target$20.00 Low Price Target$13.00 Potential Upside/Downside+135.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.31 million Price / Sales5.01 Cash FlowN/A Price / Cash FlowN/A Book Value($9.87) per share Price / Book-0.71Miscellaneous Outstanding Shares1,653,000Free Float1,636,000Market Cap$11.57 million OptionableOptionable Beta2.15 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:KZIA) was last updated on 10/20/2025 by MarketBeat.com Staff From Our Partners$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.